CBAY CymaBay Therapeutics Inc

Price (delayed)

$3.905

Market cap

$269.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.81

Enterprise value

$227.23M

Highlights
CymaBay Therapeutics's debt has decreased by 31% YoY and by 11% from the previous quarter
The quick ratio has increased by 7% year-on-year and by 7% since the previous quarter
CymaBay Therapeutics's net income has increased by 40% YoY but it has decreased by 9% from the previous quarter
CymaBay Therapeutics's EPS has increased by 40% YoY but it has decreased by 9% from the previous quarter
CBAY's equity is down by 27% YoY and by 11% QoQ

Key stats

What are the main financial stats of CBAY
Market
Shares outstanding
69M
Market cap
$269.43M
Enterprise value
$227.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.11
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$55.45M
EBITDA
-$54.81M
Free cash flow
-$50.69M
Per share
EPS
-$0.81
Free cash flow per share
-$0.74
Book value per share
$1.85
Revenue per share
$0
TBVPS
$1.98
Balance sheet
Total assets
$136.68M
Total liabilities
$9.04M
Debt
$1.13M
Equity
$127.65M
Working capital
$125.36M
Liquidity
Debt to equity
0.01
Current ratio
16.85
Quick ratio
15.86
Net debt/EBITDA
0.77
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.9%
Return on equity
-37.4%
Return on invested capital
-57.1%
Return on capital employed
-43.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CBAY stock price

How has the CymaBay Therapeutics stock price performed over time
Intraday
1.43%
1 week
-2.86%
1 month
-10.02%
1 year
-27.01%
YTD
-31.97%
QTD
-10.44%

Financial performance

How have CymaBay Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$56.29M
Net income
-$55.45M
Gross margin
N/A
Net margin
N/A
CymaBay Therapeutics's operating income has increased by 42% YoY but it has decreased by 7% from the previous quarter
CymaBay Therapeutics's net income has increased by 40% YoY but it has decreased by 9% from the previous quarter

Growth

What is CymaBay Therapeutics's growth rate over time

Valuation

What is CymaBay Therapeutics stock price valuation
P/E
N/A
P/B
2.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CymaBay Therapeutics's EPS has increased by 40% YoY but it has decreased by 9% from the previous quarter
The P/B is 73% lower than the 5-year quarterly average of 7.7 and 17% lower than the last 4 quarters average of 2.5
CBAY's equity is down by 27% YoY and by 11% QoQ

Efficiency

How efficient is CymaBay Therapeutics business performance
CBAY's ROE is up by 18% YoY but it is down by 17% QoQ
CBAY's ROA is down by 18% QoQ but it is up by 17% YoY
CBAY's ROIC is down by 18% QoQ and by 3.3% YoY

Dividends

What is CBAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CBAY.

Financial health

How did CymaBay Therapeutics financials performed over time
CBAY's total liabilities is down by 33% year-on-year and by 19% since the previous quarter
CBAY's total assets is down by 28% YoY and by 11% from the previous quarter
CymaBay Therapeutics's debt is 99% less than its equity
CymaBay Therapeutics's debt has decreased by 31% YoY and by 11% from the previous quarter
CBAY's equity is down by 27% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.